Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network.
Sharing data and resources across rare disease research networks speeds progress and builds readiness for faster clinical trials when treatments emerge.
This review describes the NIH-funded Rare Diseases Clinical Research Network (RDCRN)'s collaborative governance model and cross-consortia initiatives, demonstrating how shared infrastructure, patient advocacy engagement, and standardized data collection advance rare disease research and trial readiness. The COVID-19 pandemic prompted priority cross-consortia efforts that yielded new diagnostic tools and endpoint harmonization across multiple rare diseases.
What the study was
- Study design
- Descriptive/methodological review
- Population
- Rare disease patients enrolled in RDCRN consortia
- Category
- Public Health
- Maturity
- Validated
- Journal
- Clinical and Translational Science
Why it surfaced
Methodological/infrastructure paper; relevant to rare disease trial readiness but low direct clinical signal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.